• AON successfully alleviated the myotonic phenotype

  2019-10-22

  

  AON successfully alleviated the myotonic phenotype in DM model mice [18], [23]. To screen for an optimal AON sequence, we used 25-mer phosphorothioate 2′ O-methyl RNA molecules that covered the exon 6B or exon 7A. Unexpectedly, AON 7A (+63−8) which covers the boundary of intron 7A and exon 7A enhanc

• TgTCEA from petals TgTCEA and

  2019-10-22

  

  TgTCEA from petals (TgTCEA1) and TgTCEB from pollen grains (TgTCEB1) were used throughout the study. The recombinant enzymes were expressed in , and purified as the His-tag-free forms as described previously., Enzyme reactions were performed at 4 mM substrates under the same conditions as described

• TraM is one of two

  2019-10-22

  

  TraM is one of two transfer proteins from pIP501 T4SS that have structural similarity to the A. tumefaciens VirB8 protein (Fercher et al., 2016, Goessweiner-Mohr et al., 2013), a central member of the inner membrane complex (Bailey et al., 2006, Guglielmini et al., 2014, Trokter et al., 2014). VirB8

• br Acknowledgments This work was supported by Grants from

  2019-10-22

  

  Acknowledgments This work was supported by Grants from the National Research Foundation (2010-0000782) and the National Center for GM Crops (PJ008152) of the Next Generation BioGreen 21 Program funded by the Rural Development Administration, Republic of Korea, to W.T.K. Introduction Ubiquityl

• Currently multiple clinical trials of CSF CSF

  2019-10-21

  

  Currently, multiple clinical trials of CSF-1/CSF-1R-targeting agents in combination with standard treatment modalities and immunotherapies are underway (Table 1). In particular, results for combinations with checkpoint blockade inhibitors and other immunotherapeutic approaches are eagerly awaited.

• br Cytokine impact on ILC

  2019-10-21

  

  Cytokine impact on ILC fate Increasing evidence shows that ILC2 and ILC3 may convert into ILC1-like BAY 80-6946 by downregulating either GATA3 or RORγt, respectively, upregulating T-bet and gaining the capacity for IFN-γ production [60,61]. This process, often referred to as ‘ILC plasticity’, may

• br Results and Discussion br Experimental Procedures br Ackn

  2019-10-21

  

  Results and Discussion Experimental Procedures Acknowledgments The ubiquitin–proteasome system (UPS) is important for biological processes such as protein degradation and protein function regulation. In general, poly-ubiquitinated proteins are degraded by proteasomes, and some proteins ac

• br Results and discussion br Conclusion We have constructed

  2019-10-21

  

  Results and discussion Conclusion We have constructed a series of potent and greatly selective DPP-4 inhibitors with pyrazolo[1,5-a]pyrimidin-7(4H)-one core surrogates. The modification of the core led us to b2 which has IC50 of 80 nM and > 1000 fold selectivity over DPP-8 and DPP-9. We utiliz

• DGK negatively regulated the extension of long axon

  2019-10-21

  

  DGKδ negatively regulated the extension of long axon/neurite (Fig. 4, Fig. 5, Fig. 6). The results strongly suggest that deficiency of DGKδ induces OCD-like behavior by enhancing axon/neurite outgrowth. DGKδ positively regulates growth factor signaling (Crotty et al., 2006). Therefore, DGKδ deficien

• Air trapping at the small airways

  2019-10-21

  

  Air-trapping at the small airways is related to severe Azaserine synthesis (Bjermer, 2014), and acute exacerbation (Mahut et al., 2010). Although asthma patients are generally treated with inhaled corticosteroid (ICS) or with ICS and long-acting β2 agonist (LABA), the efficacy of such treatment depe

• br Results and discussion br Conclusion In this investigatio

  2019-10-21

  

  Results and discussion Conclusion In this investigation, pharmacophore models of CK1 inhibitors were developed using a pharmacophore modeling protocol proposed by us. The optimal pharmacophore hypothesis, Hypo2, was adopted to retrieve potential CK1 inhibitors from the commercial chemical data

• Currently according to Mielke and colleagues drugs with US

  2019-10-21

  

  Currently, according to Mielke and colleagues [103], drugs with US Food and Drug Administration (FDA) approval for Alzheimer therapy include the following: galantamine (Razadyn®, 4aS,6R,8aS-5,6,9,10,11,12- hexahydro- 3-methoxy- 11-methyl- 4aH [1], benzofuro[3a,3,2-ef] [2] benzazepin- 6-ol), rivastig

• protease inhibitor cocktail receptor There is a considerable

  2019-10-21

  

  There is a considerable molecular genetic heterogeneity within ES/PNET. As mentioned above, either or can rearrange with in these gene fusions. Furthermore, for either gene fusion, additional heterogeneity stems from the location of the genomic breakpoints of the translocation, resulting in diffe

• Recently roflumilast has been approved as

  2019-10-21

  

  Recently, roflumilast has been approved as the first selective PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD) [2]. Roflumilast has been suggested to target several different pathogenetic mechanisms, including inflammation, fibrotic, emphysematous and vascular remode

• br Disclosure statement br Acknowledgements This research

  2019-10-21

  

  Disclosure statement Acknowledgements This research was supported by grants from the National Institutes of Health, NS046400 and AG022971 (SD), and a fellowship from the Korea Research Foundation, KRF-2007-357-E00016 (YTK). The authors thank Dr. Barbara Crain for assistance with the immunologi

15309 records 894/1021 page Previous Next First page 上5页 891892893894895 下5页 Last page